Nanosuspension Formulation of Itraconazole Eliminates the Negative Inotropic Effect of SPORANOX® in Dogs

Journal of Medical Toxicology

Volumn 6, Issue 3, 2010, Pages 331-336

  McKee, Jeff ^a   Rabinow, Barrett ^a   Cook, Chyung ^a   Gass, Jerry ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Dog; Itraconazole; Ventricular contractility

Indexed keywords

ITRACONAZOLE; ANTIFUNGAL AGENT; NANOPARTICLE; SUSPENSION;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG FORMULATION; HEART LEFT VENTRICLE; HEART MUSCLE CONTRACTILITY; INOTROPISM; LIGHT SCATTERING; MALE; NONHUMAN; OSMOLALITY; PARTICLE SIZE; PHYSICAL CHEMISTRY; SUSPENSION; SYSTOLIC BLOOD PRESSURE; ZETA POTENTIAL; ANIMAL; BLOOD; CHEMICAL PHENOMENA; CHEMISTRY; DOG; DRUG EFFECTS; DRUG STABILITY; HEART CONTRACTION; TOXICITY;

ANIMALS; ANTIFUNGAL AGENTS; DEPRESSION, CHEMICAL; DOGS; DRUG STABILITY; ITRACONAZOLE; MALE; MYOCARDIAL CONTRACTION; NANOPARTICLES; SUSPENSIONS;

EID: 77956142594     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-010-0025-6     Document Type: Article

References (20)

1. Pfaller M, Wenzel R (2003) The epidemiology of fungal infections. In: Elias E, McGinnis M, Pfaller M (eds) Clinical mycology. Elsevier Science, New York.
2. Pappas P, Kauffman C, Andes D et al (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48: 503-535.
3. Vehreschild J, Sieniawski M, Reuter S et al (2009) Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational registry. Int J Antimicrob Agents 34: 446-450.
4. Pappas P, Rex J, Sobel J et al (2004) Guidelines for treatment of candidiasis. Clin Infect Dis 38: 161-189.
5. Ohta K, Kosaka S, Nakao Y et al (2009) Efficacy and safety of intravenous itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematological malignancies in Japan. Int J Hematol 89: 649-655.
6. Walsh T, Anaissie E, Denning D et al (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46: 327-360.
7. Hughes W, Armstrong D, Bodey G et al (1997) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 25: 551-573.
8. Revankar S, Kirkpatrick W, McAtee R et al (1996) Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 174: 821-827.
9. Wingard J, Merz W, Rinaldi M et al (1991) Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New Engl J Med 325: 1274-1277.
10. Walsh T, Teppler H, Donowitz G et al (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. New Engl J Med 351: 1391-1402.
11. Boogaerts M, Winston D, Bow E et al (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. Ann Intern Med 135: 412-422.
12. Rabinow B, Kipp J, Papadopoulos P et al (2007) Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int J Pharm 339: 251-260.
13. Andes D (2003) In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 47: 1179-1186.
14. SPORANOX® (itraconazole) Injection package insert. Revised March 2009.
15. Ahmad S, Singer S, Leissa B (2001) Congestive heart failure associated with itraconazole. The Lancet 357: 1766-1767.
16. Kipp J, Wong J, Doty M et al (2003) Microprecipitation method for preparing submicron suspensions. US Patent No. 6607784 B2.
17. Code of Federal Regulations (2009) Title 9: Animals and animal products. Chapter 1, subchapter A, parts 1, and 3: Animal welfare. Jan 1, 2009.
18. Institute of Laboratory Animal Resources (US), Committee on Care and Use of Laboratory Animals (1996) Guide for the care and use of laboratory animals. Public Health Service, US Dept. of Health and Human Services, Bethesda.
19. Patterson S, Piper H, Starling E (1914) The regulation of the heartbeat. J Physiol 48(6): 465-513.
20. Moghimi M, Hunter C, Murray C (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53: 283-318.